Voriconazole and squamous cell carcinoma after lung transplantation: A multicenter study.
Identifieur interne : 000499 ( PubMed/Corpus ); précédent : 000498; suivant : 000500Voriconazole and squamous cell carcinoma after lung transplantation: A multicenter study.
Auteurs : B. Hamandi ; C. Fegbeutel ; F P Silveira ; E A Verschuuren ; M. Younus ; J. Mo ; J. Yan ; P. Ussetti ; P V Chin-Hong ; A. Solé ; C L Holmes-Liew ; E M Billaud ; P A Grossi ; O. Manuel ; D J Levine ; R G Barbers ; D. Hadjiliadis ; J. Aram ; L G Singer ; S. HusainSource :
- American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [ 1600-6143 ] ; 2017.
Abstract
This study evaluated the independent contribution of voriconazole to the development of squamous cell carcinoma (SCC) in lung transplant recipients, by attempting to account for important confounding factors, particularly immunosuppression. This international, multicenter, retrospective, cohort study included adult patients who underwent lung transplantation during 2005-2008. Cox regression analysis was used to assess the effects of voriconazole and other azoles, analyzed as time-dependent variables, on the risk of developing biopsy-confirmed SCC. Nine hundred lung transplant recipients were included. Median follow-up time from transplantation to end of follow-up was 3.51 years. In a Cox regression model, exposure to voriconazole alone (adjusted hazard ratio 2.39, 95% confidence interval 1.31-4.37) and exposure to voriconazole and other azole(s) (adjusted hazard ratio 3.45, 95% confidence interval 1.07-11.06) were associated with SCC compared with those unexposed after controlling for important confounders including immunosuppressants. Exposure to voriconazole was associated with increased risk of SCC of the skin in lung transplant recipients. Residual confounding could not be ruled out because of the use of proxy variables to control for some confounders. Benefits of voriconazole use when prescribed to lung transplant recipients should be carefully weighed versus the potential risk of SCC. EU PAS registration number: EUPAS5269.
DOI: 10.1111/ajt.14500
PubMed: 28898527
Links to Exploration step
pubmed:28898527Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Voriconazole and squamous cell carcinoma after lung transplantation: A multicenter study.</title><author><name sortKey="Hamandi, B" sort="Hamandi, B" uniqKey="Hamandi B" first="B" last="Hamandi">B. Hamandi</name><affiliation><nlm:affiliation>Department of Pharmacy, University Health Network, Toronto, ON, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Fegbeutel, C" sort="Fegbeutel, C" uniqKey="Fegbeutel C" first="C" last="Fegbeutel">C. Fegbeutel</name><affiliation><nlm:affiliation>Department of Cardiothoracic, Transplant, and Vascular Surgery, Hannover Medical School, Hannover, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Silveira, F P" sort="Silveira, F P" uniqKey="Silveira F" first="F P" last="Silveira">F P Silveira</name><affiliation><nlm:affiliation>Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Verschuuren, E A" sort="Verschuuren, E A" uniqKey="Verschuuren E" first="E A" last="Verschuuren">E A Verschuuren</name><affiliation><nlm:affiliation>Department of Pulmonary Diseases, University Hospital Groningen, Groningen, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Younus, M" sort="Younus, M" uniqKey="Younus M" first="M" last="Younus">M. Younus</name><affiliation><nlm:affiliation>Pfizer Inc., New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mo, J" sort="Mo, J" uniqKey="Mo J" first="J" last="Mo">J. Mo</name><affiliation><nlm:affiliation>Pfizer Inc., New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Yan, J" sort="Yan, J" uniqKey="Yan J" first="J" last="Yan">J. Yan</name><affiliation><nlm:affiliation>Pfizer Inc., New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ussetti, P" sort="Ussetti, P" uniqKey="Ussetti P" first="P" last="Ussetti">P. Ussetti</name><affiliation><nlm:affiliation>Respiratory Department, Hospital Puerta de Hierro, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Chin Hong, P V" sort="Chin Hong, P V" uniqKey="Chin Hong P" first="P V" last="Chin-Hong">P V Chin-Hong</name><affiliation><nlm:affiliation>Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Sole, A" sort="Sole, A" uniqKey="Sole A" first="A" last="Solé">A. Solé</name><affiliation><nlm:affiliation>Respiratory Department, University and Polytechnic Hospital La Fe, Universidad de Valencia, Valencia, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Holmes Liew, C L" sort="Holmes Liew, C L" uniqKey="Holmes Liew C" first="C L" last="Holmes-Liew">C L Holmes-Liew</name><affiliation><nlm:affiliation>Lung Research, Hanson Institute, and Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Billaud, E M" sort="Billaud, E M" uniqKey="Billaud E" first="E M" last="Billaud">E M Billaud</name><affiliation><nlm:affiliation>Service de Pharmacologie, AP-HP, Hôpital Européen G Pompidou, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Grossi, P A" sort="Grossi, P A" uniqKey="Grossi P" first="P A" last="Grossi">P A Grossi</name><affiliation><nlm:affiliation>Infectious Diseases Department, University of Insubria, Varese, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Manuel, O" sort="Manuel, O" uniqKey="Manuel O" first="O" last="Manuel">O. Manuel</name><affiliation><nlm:affiliation>Infectious Diseases Service and Transplantation Center, University Hospital of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Levine, D J" sort="Levine, D J" uniqKey="Levine D" first="D J" last="Levine">D J Levine</name><affiliation><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, University of Texas Health Science Center San Antonio, San Antonio, TX, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Barbers, R G" sort="Barbers, R G" uniqKey="Barbers R" first="R G" last="Barbers">R G Barbers</name><affiliation><nlm:affiliation>Division of Pulmonary and Critical Care, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hadjiliadis, D" sort="Hadjiliadis, D" uniqKey="Hadjiliadis D" first="D" last="Hadjiliadis">D. Hadjiliadis</name><affiliation><nlm:affiliation>Department of Medicine, University of Pennsylvania, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Aram, J" sort="Aram, J" uniqKey="Aram J" first="J" last="Aram">J. Aram</name><affiliation><nlm:affiliation>Pfizer Inc., New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Singer, L G" sort="Singer, L G" uniqKey="Singer L" first="L G" last="Singer">L G Singer</name><affiliation><nlm:affiliation>Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Husain, S" sort="Husain, S" uniqKey="Husain S" first="S" last="Husain">S. Husain</name><affiliation><nlm:affiliation>Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28898527</idno><idno type="pmid">28898527</idno><idno type="doi">10.1111/ajt.14500</idno><idno type="wicri:Area/PubMed/Corpus">000499</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000499</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Voriconazole and squamous cell carcinoma after lung transplantation: A multicenter study.</title><author><name sortKey="Hamandi, B" sort="Hamandi, B" uniqKey="Hamandi B" first="B" last="Hamandi">B. Hamandi</name><affiliation><nlm:affiliation>Department of Pharmacy, University Health Network, Toronto, ON, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Fegbeutel, C" sort="Fegbeutel, C" uniqKey="Fegbeutel C" first="C" last="Fegbeutel">C. Fegbeutel</name><affiliation><nlm:affiliation>Department of Cardiothoracic, Transplant, and Vascular Surgery, Hannover Medical School, Hannover, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Silveira, F P" sort="Silveira, F P" uniqKey="Silveira F" first="F P" last="Silveira">F P Silveira</name><affiliation><nlm:affiliation>Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Verschuuren, E A" sort="Verschuuren, E A" uniqKey="Verschuuren E" first="E A" last="Verschuuren">E A Verschuuren</name><affiliation><nlm:affiliation>Department of Pulmonary Diseases, University Hospital Groningen, Groningen, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Younus, M" sort="Younus, M" uniqKey="Younus M" first="M" last="Younus">M. Younus</name><affiliation><nlm:affiliation>Pfizer Inc., New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mo, J" sort="Mo, J" uniqKey="Mo J" first="J" last="Mo">J. Mo</name><affiliation><nlm:affiliation>Pfizer Inc., New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Yan, J" sort="Yan, J" uniqKey="Yan J" first="J" last="Yan">J. Yan</name><affiliation><nlm:affiliation>Pfizer Inc., New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ussetti, P" sort="Ussetti, P" uniqKey="Ussetti P" first="P" last="Ussetti">P. Ussetti</name><affiliation><nlm:affiliation>Respiratory Department, Hospital Puerta de Hierro, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Chin Hong, P V" sort="Chin Hong, P V" uniqKey="Chin Hong P" first="P V" last="Chin-Hong">P V Chin-Hong</name><affiliation><nlm:affiliation>Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Sole, A" sort="Sole, A" uniqKey="Sole A" first="A" last="Solé">A. Solé</name><affiliation><nlm:affiliation>Respiratory Department, University and Polytechnic Hospital La Fe, Universidad de Valencia, Valencia, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Holmes Liew, C L" sort="Holmes Liew, C L" uniqKey="Holmes Liew C" first="C L" last="Holmes-Liew">C L Holmes-Liew</name><affiliation><nlm:affiliation>Lung Research, Hanson Institute, and Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Billaud, E M" sort="Billaud, E M" uniqKey="Billaud E" first="E M" last="Billaud">E M Billaud</name><affiliation><nlm:affiliation>Service de Pharmacologie, AP-HP, Hôpital Européen G Pompidou, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Grossi, P A" sort="Grossi, P A" uniqKey="Grossi P" first="P A" last="Grossi">P A Grossi</name><affiliation><nlm:affiliation>Infectious Diseases Department, University of Insubria, Varese, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Manuel, O" sort="Manuel, O" uniqKey="Manuel O" first="O" last="Manuel">O. Manuel</name><affiliation><nlm:affiliation>Infectious Diseases Service and Transplantation Center, University Hospital of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Levine, D J" sort="Levine, D J" uniqKey="Levine D" first="D J" last="Levine">D J Levine</name><affiliation><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, University of Texas Health Science Center San Antonio, San Antonio, TX, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Barbers, R G" sort="Barbers, R G" uniqKey="Barbers R" first="R G" last="Barbers">R G Barbers</name><affiliation><nlm:affiliation>Division of Pulmonary and Critical Care, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hadjiliadis, D" sort="Hadjiliadis, D" uniqKey="Hadjiliadis D" first="D" last="Hadjiliadis">D. Hadjiliadis</name><affiliation><nlm:affiliation>Department of Medicine, University of Pennsylvania, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Aram, J" sort="Aram, J" uniqKey="Aram J" first="J" last="Aram">J. Aram</name><affiliation><nlm:affiliation>Pfizer Inc., New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Singer, L G" sort="Singer, L G" uniqKey="Singer L" first="L G" last="Singer">L G Singer</name><affiliation><nlm:affiliation>Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Husain, S" sort="Husain, S" uniqKey="Husain S" first="S" last="Husain">S. Husain</name><affiliation><nlm:affiliation>Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada.</nlm:affiliation></affiliation></author></analytic><series><title level="j">American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</title><idno type="eISSN">1600-6143</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This study evaluated the independent contribution of voriconazole to the development of squamous cell carcinoma (SCC) in lung transplant recipients, by attempting to account for important confounding factors, particularly immunosuppression. This international, multicenter, retrospective, cohort study included adult patients who underwent lung transplantation during 2005-2008. Cox regression analysis was used to assess the effects of voriconazole and other azoles, analyzed as time-dependent variables, on the risk of developing biopsy-confirmed SCC. Nine hundred lung transplant recipients were included. Median follow-up time from transplantation to end of follow-up was 3.51 years. In a Cox regression model, exposure to voriconazole alone (adjusted hazard ratio 2.39, 95% confidence interval 1.31-4.37) and exposure to voriconazole and other azole(s) (adjusted hazard ratio 3.45, 95% confidence interval 1.07-11.06) were associated with SCC compared with those unexposed after controlling for important confounders including immunosuppressants. Exposure to voriconazole was associated with increased risk of SCC of the skin in lung transplant recipients. Residual confounding could not be ruled out because of the use of proxy variables to control for some confounders. Benefits of voriconazole use when prescribed to lung transplant recipients should be carefully weighed versus the potential risk of SCC. EU PAS registration number: EUPAS5269.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">28898527</PMID><DateCreated><Year>2017</Year><Month>09</Month><Day>12</Day></DateCreated><DateRevised><Year>2017</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-6143</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2017</Year><Month>Sep</Month><Day>12</Day></PubDate></JournalIssue><Title>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</Title><ISOAbbreviation>Am. J. Transplant.</ISOAbbreviation></Journal><ArticleTitle>Voriconazole and squamous cell carcinoma after lung transplantation: A multicenter study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/ajt.14500</ELocationID><Abstract><AbstractText>This study evaluated the independent contribution of voriconazole to the development of squamous cell carcinoma (SCC) in lung transplant recipients, by attempting to account for important confounding factors, particularly immunosuppression. This international, multicenter, retrospective, cohort study included adult patients who underwent lung transplantation during 2005-2008. Cox regression analysis was used to assess the effects of voriconazole and other azoles, analyzed as time-dependent variables, on the risk of developing biopsy-confirmed SCC. Nine hundred lung transplant recipients were included. Median follow-up time from transplantation to end of follow-up was 3.51 years. In a Cox regression model, exposure to voriconazole alone (adjusted hazard ratio 2.39, 95% confidence interval 1.31-4.37) and exposure to voriconazole and other azole(s) (adjusted hazard ratio 3.45, 95% confidence interval 1.07-11.06) were associated with SCC compared with those unexposed after controlling for important confounders including immunosuppressants. Exposure to voriconazole was associated with increased risk of SCC of the skin in lung transplant recipients. Residual confounding could not be ruled out because of the use of proxy variables to control for some confounders. Benefits of voriconazole use when prescribed to lung transplant recipients should be carefully weighed versus the potential risk of SCC. EU PAS registration number: EUPAS5269.</AbstractText><CopyrightInformation>© 2017 The American Society of Transplantation and the American Society of Transplant Surgeons.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hamandi</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fegbeutel</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic, Transplant, and Vascular Surgery, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silveira</LastName><ForeName>F P</ForeName><Initials>FP</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verschuuren</LastName><ForeName>E A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Diseases, University Hospital Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Younus</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mo</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ussetti</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Respiratory Department, Hospital Puerta de Hierro, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chin-Hong</LastName><ForeName>P V</ForeName><Initials>PV</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solé</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Respiratory Department, University and Polytechnic Hospital La Fe, Universidad de Valencia, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes-Liew</LastName><ForeName>C L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Lung Research, Hanson Institute, and Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Billaud</LastName><ForeName>E M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Service de Pharmacologie, AP-HP, Hôpital Européen G Pompidou, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grossi</LastName><ForeName>P A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, University of Insubria, Varese, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manuel</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Infectious Diseases Service and Transplantation Center, University Hospital of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levine</LastName><ForeName>D J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, University of Texas Health Science Center San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbers</LastName><ForeName>R G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hadjiliadis</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Pennsylvania, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aram</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singer</LastName><ForeName>L G</ForeName><Initials>LG</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-2693-8676</Identifier><AffiliationInfo><Affiliation>Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Husain</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Transplant</MedlineTA><NlmUniqueID>100968638</NlmUniqueID><ISSNLinking>1600-6135</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antibiotic: antifungal</Keyword><Keyword MajorTopicYN="N">clinical research/practice</Keyword><Keyword MajorTopicYN="N">complication: malignant</Keyword><Keyword MajorTopicYN="N">health services and outcomes research</Keyword><Keyword MajorTopicYN="N">infection and infectious agents - fungal</Keyword><Keyword MajorTopicYN="N">infectious disease</Keyword><Keyword MajorTopicYN="N">lung disease</Keyword><Keyword MajorTopicYN="N">lung transplantation/pulmonology</Keyword><Keyword MajorTopicYN="N">patient safety</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>06</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>08</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>08</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28898527</ArticleId><ArticleId IdType="doi">10.1111/ajt.14500</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000499 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000499 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28898527
|texte= Voriconazole and squamous cell carcinoma after lung transplantation: A multicenter study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28898527" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |